Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cilostazol
Drug ID BADD_D00466
Description Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Indications and Usage For the reduction of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
Marketing Status Prescription; Discontinued
ATC Code B01AC23
DrugBank ID DB01166
KEGG ID D01896
MeSH ID D000077407
PubChem ID 2754
TTD Drug ID D03VPC
NDC Product Code 46438-0632; 70518-2208; 72189-116; 66039-113; 0185-0223; 71610-037; 0093-2064; 0093-2065; 60505-2521; 70518-2714; 46438-0633; 50090-5329; 0054-0028; 50268-177; 70436-157; 63629-8796; 70518-2200; 0054-0044; 50268-176; 42291-453; 58175-0379; 70436-156; 63629-8795; 67680-001; 60505-2522; 42185-7038; 63415-0034; 46438-1109
Synonyms Cilostazol | 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone | OPC 13013 | OPC-13013 | Pletal
Chemical Information
Molecular Formula C20H27N5O2
CAS Registry Number 73963-72-1
SMILES C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vomiting07.01.07.0030.003439%
White blood cell count decreased13.01.06.012--
Tubulointerstitial nephritis20.05.02.0020.004126%Not Available
Tachyarrhythmia02.03.02.0080.001375%Not Available
Bradyarrhythmia02.03.02.015--Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000359%Not Available
Lacunar infarction17.08.01.016; 24.04.06.0090.004126%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.0220.002063%Not Available
Cerebral haematoma17.08.01.014; 24.07.04.0060.000538%Not Available
Haemorrhage24.07.01.0020.002751%Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Vasodilation procedure25.03.01.001--Not Available
Haemobilia24.07.01.049; 09.01.08.0090.002063%Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.01.01.003--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Haemorrhagic diathesis01.01.03.003; 24.07.01.020--Not Available
Cystitis noninfective20.03.02.001--
Acute kidney injury20.01.03.0160.004814%
Epidural haemorrhage24.07.04.017; 17.08.05.004; 12.01.10.013--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages